KalVista Pharmaceuticals, Inc. (KALV) — Stock Score Summary

KalVista Pharmaceuticals, Inc. (KALV) has a MoatMap StockRank of 78/100 based on Quality (30/100), Value (47/100), and Momentum (82/100) factor scores. The current signal is BUY. KalVista is a clinical-stage biotech focused on hereditary angioedema. It fails our core Terry Smith quality filter as it is pre-revenue, lacks positive ROIC, and has no established cash flows, making it an inappropriate fit for a concentrated compounding portfolio.

KalVista Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors. The company's primary therapeutic focus is on oral treatments for hereditary angioedema (HAE), aiming to disrupt a market currently dominated by injectable therapies. Its competitive advantage lies in its proprietary platform of highly selective plasma kallikrein inhibitors, offering patients a more convenient oral dosing alternative.

Key Financial Metrics

Price$26.95
Market Cap$1.4B
P/E (Forward)22.52
Price/Book-508.49
Return on Invested Capital-62.7%
Gross Margin51.1%
Operating Margin-57.4%

KalVista Pharmaceuticals, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is KalVista Pharmaceuticals, Inc.’s (KALV) StockRank?
MoatMap’s StockRank for KalVista Pharmaceuticals, Inc. (KALV) is 78/100, with a Buy signal. It is a composite of Quality (30), Value (47), and Momentum (82) factor ranks across MoatMap’s 19,000+ stock universe.
Does KalVista Pharmaceuticals, Inc. have an economic moat?
KalVista Pharmaceuticals, Inc. (KALV) has a Quality factor score of 30/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is KalVista Pharmaceuticals, Inc. a buy, hold, or sell?
MoatMap’s current signal for KalVista Pharmaceuticals, Inc. (KALV) is Buy, based on a StockRank of 78/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is KalVista Pharmaceuticals, Inc. in?
KalVista Pharmaceuticals, Inc. (KALV) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksKALV deep dive reportAI ChampionsHow we score stocksSense-check another stock